BioSpace3h
Tris Pharma Records Late-Stage Win for Non-Opioid Painkiller
Cebranopadol, a dual-NMR agonist, reached the primary endpoint in a Phase III trial and matched placebo for safety, a ...
BioSpace11h
J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
BioSpace11h
FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets
The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a ...
BioSpace8h
J&J Says Deals Likely to Shrink After $14.6B Intra-Cellular Buy
On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...
BioSpace10h
Almost 5 Years into $5B Galapagos Partnership, Gilead Execs Start Over With New Spinoff
Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...
BioSpace10h
WHO Withdrawal, CGT Access, IRA: Trump’s Initial Policies Raise Questions for Biopharma
At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...
BioSpace11h
Chinese Biotech Ascentage Aims For $134M IPO
Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia ...
BioSpace14h
Trump Takes Over, Wegovy Still Trails Zepbound and BioSpace Recaps JPM
Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...